P Pharming Group NV
P
Closed
0.975 2.09
Overview
Share price change
24h
Min
0.94
Max
0.962
Income | 6.7M 1.6M |
|---|---|
Sales | 17M 89M |
P/E Sector Avg | 88.28 68.51 |
EPS | -0.006 |
Profit margin | 1.774 |
Employees | 407 |
EBITDA | 7.1M 5M |
Next Earnings | 5 Nov 2026 |
|---|
Market Cap | -173M 625M |
|---|---|
Previous open | -1.11 |
Previous close | 0.975 |
Pharming Group NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pharming Group NV Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.